Ferrostatin-1 specifically targets mitochondrial iron-sulfur clusters and aconitase to improve cardiac function in Sirtuin 3 cardiomyocyte knockout mice

  • 0Department of Pharmacology & Toxicology, University of Mississippi Medical Center, School of Medicine, Jackson, MS 39216, USA.

Summary

This summary is machine-generated.

Mitochondrial ferroptosis, driven by Sirtuin 3 (SIRT3) loss in heart cells, causes heart failure. Inhibiting ferroptosis with ferrostatin-1 improved heart function by targeting mitochondrial pathways.

Area Of Science

  • Cardiovascular Research
  • Mitochondrial Biology
  • Cell Death Mechanisms

Background

  • Ferroptosis, an iron-dependent cell death, is implicated in ischemic heart disease.
  • Sirtuin 3 (SIRT3) is linked to ferroptosis and cardiac fibrosis.
  • Mitochondrial dysfunction is a key factor in heart failure.

Purpose Of The Study

  • To investigate if SIRT3 knockout in cardiomyocytes (SIRT3cKO) promotes mitochondrial ferroptosis.
  • To determine if blocking ferroptosis can ameliorate mitochondrial dysfunction in the context of SIRT3 deficiency.
  • To explore the role of SIRT3 as a mitochondrial deacetylase in ferroptosis.

Main Methods

  • Comparative analysis of mitochondrial and cytosolic fractions from SIRT3cKO and SIRT3loxp mice.
  • Echocardiography to assess cardiac function (EF% and FS%).
  • Analysis of protein acetylation, key ferroptosis regulators (GPX4, frataxin, aconitase), and oxidative stress markers (4-hydroxynonenal).
  • Treatment with ferroptosis inhibitor ferrostatin-1 (Fer-1) in SIRT3cKO mice.

Main Results

  • SIRT3cKO mice exhibited heart failure with reduced EF% and FS%.
  • Loss of SIRT3 led to increased mitochondrial acetylation, including acetylated p53, and decreased mitochondrial GPX4, frataxin, and aconitase.
  • Ferrostatin-1 treatment improved cardiac function, increased GPX4 and aconitase, and restored mitochondrial integrity in SIRT3cKO mice.

Conclusions

  • SIRT3 is a critical mitochondrial deacetylase regulating ferroptosis.
  • Inhibition of ferroptosis ameliorates cardiac dysfunction by targeting mitochondrial aconitase and iron-sulfur clusters.
  • Blocking mitochondrial ferroptosis presents a potential therapeutic strategy for mitochondrial cardiomyopathies.